<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352845</url>
  </required_header>
  <id_info>
    <org_study_id>B1971016</org_study_id>
    <secondary_id>6108A1-2004</secondary_id>
    <secondary_id>2009-014492-46</secondary_id>
    <nct_id>NCT01352845</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged &gt;=18 to &lt;26 Years.</brief_title>
  <acronym>B1971016</acronym>
  <official_title>A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged &gt;=18 To &lt;26 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at a new vaccine that might prevent meningococcal disease, and will
      study the immune response elicited by this vaccine when given to healthy young adults. The
      study will also look at the safety of the new vaccine as well as how it is tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Greater Than or Equal to(&gt;=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA&gt;=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1</measure>
    <time_frame>One month after third bivalent rLP2086 vaccination</time_frame>
    <description>Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point. This outcome measure was planned to be analyzed for Group 1 only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination</measure>
    <time_frame>Within 7 days after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Second Vaccination</measure>
    <time_frame>Within 7 days after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Third Vaccination</measure>
    <time_frame>Within 7 days after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination</measure>
    <time_frame>Within 7 days after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination</measure>
    <time_frame>Within 7 days after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination</measure>
    <time_frame>Within 7 days after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After First Vaccination</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination</measure>
    <time_frame>Within 30 days after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase</measure>
    <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination</measure>
    <time_frame>Within 30 days after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase</measure>
    <time_frame>From 1 month after third vaccination up to 6 months after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase</measure>
    <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period</measure>
    <time_frame>From the first vaccination up to 6 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination</measure>
    <time_frame>Within 30 days after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase</measure>
    <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase</measure>
    <time_frame>From 1 month after third vaccination up to 6 months after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Medically Attended Adverse Event Throughout the Study Period</measure>
    <time_frame>From the first vaccination up to 6 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination</measure>
    <time_frame>Within 30 days after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase</measure>
    <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase</measure>
    <time_frame>From 1 month after third vaccination up to 6 months after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period</measure>
    <time_frame>From the first vaccination up to 6 month after the third vaccination the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination</measure>
    <time_frame>Within 30 minutes after first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination</measure>
    <time_frame>Within 30 minutes after second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Third Vaccination</measure>
    <time_frame>Within 30 minutes after third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days Participants Missed School or Work Due to AE During the Vaccination Phase</measure>
    <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;= Lower Limit of Quantification for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before first vaccination, 1 month after third vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, &gt;=1:128 for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before first vaccination, 1 month after third vaccination (Vac)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before first vaccination, 1 month after third vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Composite hSBA Titer &gt;=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before vaccination 1, 1 Month after Vaccination 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>One month after second Bivalent rLP2086 vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before Vaccination (Vac) 1, 1 Month after Vac 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before Vaccination (Vac) 1, 1 Month after Vac 2, 3</time_frame>
    <description>Results for PMB80[A22] 1:16, PMB2001[A56] 1:8, PMB2948[B24] 1:8 and PMB2707[B44] 1:8 are reported under secondary endpoint 'Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>Before Vaccination (Vac) 1, 1 Month after Vac 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination</measure>
    <time_frame>One month after third bivalent rLP2086 vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</measure>
    <time_frame>One month after third bivalent rLP2086 vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3301</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>rLP2086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Steril normal saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086</intervention_name>
    <description>0.5 mL dose, given at 0, 2 and 6 months</description>
    <arm_group_label>rLP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL dose, given at 0, 2 and 6 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject aged &gt;=18 and &lt;26 years at the time of enrollment.

          2. Healthy subject as determined by medical history, physical examination, and judgment
             of the investigator.

          3. Negative urine pregnancy test for all female subjects.

        Exclusion Criteria:

          1. Previous vaccination with any meningococcal serogroup B vaccine.

          2. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a
             3-dose series during the period between Visit 1 and 28 days after the second
             vaccination.

          3. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving
             allergen immunotherapy with a licensed product and are not on stable maintenance
             doses.

          4. A known or suspected defect of the immune system that would prevent an immune response
             to the vaccine, such as subjects with congenital or acquired defects in B cell
             function, those receiving chronic systemic (oral, intravenous, or intramuscular)
             corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the
             United States with terminal complement deficiency are excluded from participation in
             this study.

          5. Significant neurological disorder or history of seizure (excluding simple febrile
             seizure).

          6. Current chronic use of systemic antibiotics.

          7. Received any investigational vaccines, drugs, or devices within 28 days before
             administration of the first study vaccination.

          8. Any neuroinflammatory or autoimmune condition, including, but not limited to,
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Desert Clinical Research, LLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./ Fiel Family and Sports Medicine, PC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./ Fiel Family and Sports Medicine, PC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollyood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research Inc.</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milford Emergency Associates, Inc.</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Urgent Care</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Clinical Research, LLC</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research,</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEAK Research, LLC</name>
      <address>
        <city>Upper St. Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical</name>
      <address>
        <city>East Greenwich</city>
        <state>Rhode Island</state>
        <zip>02818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204-4880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Calvin Powell Professional Medical Corporation</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology - IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milestone Research</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Road Diagnostic Clinic and Medical Centre</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devonshire Clinical Research Inc.</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Vaccine Study Centre</name>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale St-Louis Inc.</name>
      <address>
        <city>Sainte-Foy, Québec</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro-Recherche Inc.</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital Skejby</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Vaccine Research Clinic</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne Graniczna Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-018</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Poradnia Medyczna Przyladek Zdrowia</name>
      <address>
        <city>Krakow</city>
        <zip>30-438</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Salmed s.c.</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Balenya</name>
      <address>
        <city>Balenya</city>
        <state>Barcelona</state>
        <zip>08550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Centelles</name>
      <address>
        <city>Centelles</city>
        <state>Barcelona</state>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP El Remei</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FOM (Fundacion Oftalmologica del Mediterraneo) - FISABIO</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971016&amp;StudyName=A%20Trial%20to%20Assess%20the%20Safety%2C%20Tolerability%2C%20and%20Immunogenicity%20of%20Bivalent%20rLP2086%20Vaccine%20When%20Given%20to%20Healthy%20Young%20Adults%20Aged%20greater%20than%3D18%20to%20less%20than26%20Years</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>January 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2016</results_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 3304 participants were randomized in this study, out of which 3293 participants received vaccination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 rLP2086</title>
          <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Saline</title>
          <description>Saline on a 0-, 2-, 6- month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2471"/>
                <participants group_id="P2" count="822"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1800"/>
                <participants group_id="P2" count="619"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="671"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Willing to Participate</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 rLP2086</title>
          <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Saline</title>
          <description>Saline on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2471"/>
            <count group_id="B2" value="822"/>
            <count group_id="B3" value="3293"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.47" spread="2.14"/>
                    <measurement group_id="B2" value="21.52" spread="2.20"/>
                    <measurement group_id="B3" value="21.48" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1452"/>
                    <measurement group_id="B2" value="482"/>
                    <measurement group_id="B3" value="1934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1019"/>
                    <measurement group_id="B2" value="340"/>
                    <measurement group_id="B3" value="1359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Greater Than or Equal to(&gt;=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA&gt;=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1</title>
        <description>Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point. This outcome measure was planned to be analyzed for Group 1 only.</description>
        <time_frame>One month after third bivalent rLP2086 vaccination</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized, who received correct investigational product, had pre/post vaccination blood drawn at pre-specified time points, had valid and determinate assay results for proposed analysis, received no prohibited treatment or prohibited vaccines, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Greater Than or Equal to(&gt;=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA&gt;=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1</title>
          <description>Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point. This outcome measure was planned to be analyzed for Group 1 only.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized, who received correct investigational product, had pre/post vaccination blood drawn at pre-specified time points, had valid and determinate assay results for proposed analysis, received no prohibited treatment or prohibited vaccines, and had no major protocol violations.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite hSBA response (N=1664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="83.1" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB80 [A22] (N=1695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="78.6" upper_limit="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 [A56] (N=1642)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="88.4" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24] (N=1675)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="77.3" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 [B44] (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="77.6" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination</title>
        <time_frame>Within 7 days after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2425"/>
                <count group_id="O2" value="798"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="82.7" upper_limit="85.6"/>
                    <measurement group_id="O2" value="11.8" lower_limit="9.6" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="40.3" upper_limit="44.3"/>
                    <measurement group_id="O2" value="10.7" lower_limit="8.6" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="35.1" upper_limit="39.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.5" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.0" upper_limit="5.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="12.5" upper_limit="15.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="4.9" upper_limit="6.8"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.1" upper_limit="8.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.6" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="14.1" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7.4" upper_limit="9.7"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.8" upper_limit="7.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Second Vaccination</title>
        <time_frame>Within 7 days after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2076"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="77.5" upper_limit="81.1"/>
                    <measurement group_id="O2" value="7.8" lower_limit="5.9" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="40.1" upper_limit="44.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.1" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="30.7" upper_limit="34.8"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.4" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.6" upper_limit="5.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="10.4" upper_limit="13.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.7" upper_limit="5.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.3" upper_limit="7.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.6" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="12.6" upper_limit="15.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.6" upper_limit="8.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Third Vaccination</title>
        <time_frame>Within 7 days after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1823"/>
                <count group_id="O2" value="624"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="78.5" upper_limit="82.2"/>
                    <measurement group_id="O2" value="6.7" lower_limit="4.9" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="33.9" upper_limit="38.4"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.6" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" lower_limit="36.6" upper_limit="41.2"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.3" upper_limit="6.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="15.4" upper_limit="18.9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.1" upper_limit="7.4"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="7.3" upper_limit="9.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.7" upper_limit="3.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="14.9" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="7.6" upper_limit="10.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="6.1" upper_limit="8.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination</title>
        <time_frame>Within 7 days after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination. Here, 'N' signifies participants with known values reporting specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination. Here, 'N' signifies participants with known values reporting specific characteristic.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2425"/>
                <count group_id="O2" value="798"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C(N=2415, 796)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degreesC(N=2415, 796)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.1" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to&lt;39 degrees C(N=2415, 796)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.4" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to 40 degrees C (N=2415, 796)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C(N=2415, 796)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Any(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.2" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Mild(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.6" upper_limit="2.8"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.2" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Moderate(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Severe(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Any(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="11.4" upper_limit="14.1"/>
                    <measurement group_id="O2" value="11.8" lower_limit="9.6" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Mild(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="9.0" upper_limit="11.5"/>
                    <measurement group_id="O2" value="9.8" lower_limit="7.8" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Moderate(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.1" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Severe(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Any(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="41.9" upper_limit="45.9"/>
                    <measurement group_id="O2" value="36.2" lower_limit="32.9" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Mild(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="22.6" upper_limit="26.1"/>
                    <measurement group_id="O2" value="22.1" lower_limit="19.2" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Moderate(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="16.4" upper_limit="19.5"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11.2" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Severe(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Any(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="48.9" upper_limit="52.9"/>
                    <measurement group_id="O2" value="39.8" lower_limit="36.4" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Mild(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="23.7" upper_limit="27.2"/>
                    <measurement group_id="O2" value="23.2" lower_limit="20.3" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Moderate(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="20.5" upper_limit="23.8"/>
                    <measurement group_id="O2" value="15.8" lower_limit="13.3" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Severe(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.7" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Any(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="16.5" upper_limit="19.7"/>
                    <measurement group_id="O2" value="9.8" lower_limit="7.8" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Mild(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="10.8" upper_limit="13.4"/>
                    <measurement group_id="O2" value="8.1" lower_limit="6.3" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Moderate(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.1" upper_limit="5.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.9" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Severe(N=2425, 798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.7" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Any(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="24.1" upper_limit="27.6"/>
                    <measurement group_id="O2" value="14.5" lower_limit="12.2" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Mild(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.7" upper_limit="14.4"/>
                    <measurement group_id="O2" value="9.6" lower_limit="7.7" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Moderate(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="10.0" upper_limit="12.6"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.1" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Severe(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.1" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Any(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="18.1" upper_limit="21.3"/>
                    <measurement group_id="O2" value="10.9" lower_limit="8.8" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Mild(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="9.1" upper_limit="11.6"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.2" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Moderate(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.8" upper_limit="9.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.3" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic medication(N=2425,798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="12.1" upper_limit="14.8"/>
                    <measurement group_id="O2" value="8.9" lower_limit="7.0" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination</title>
        <time_frame>Within 7 days after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination. Here, 'N' signifies participants with known values reporting specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination. Here, 'N' signifies participants with known values reporting specific characteristic.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2076"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C(N=2067, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.7" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.4" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degreesC(N=2067, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.4" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to&lt;39 degrees C(N=2067, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to 40 degrees C (N=2067, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C(N=2067, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.5" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.8" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.1" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.6" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="7.4" upper_limit="9.9"/>
                    <measurement group_id="O2" value="8.1" lower_limit="6.2" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.3" upper_limit="7.5"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.2" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.2" upper_limit="2.4"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.7" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="31.1" upper_limit="35.2"/>
                    <measurement group_id="O2" value="24.9" lower_limit="21.8" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="16.8" upper_limit="20.1"/>
                    <measurement group_id="O2" value="13.6" lower_limit="11.2" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="11.9" upper_limit="14.8"/>
                    <measurement group_id="O2" value="10.1" lower_limit="7.9" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.0" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.6" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="37.1" upper_limit="41.3"/>
                    <measurement group_id="O2" value="27.3" lower_limit="24.1" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="18.8" upper_limit="22.4"/>
                    <measurement group_id="O2" value="13.9" lower_limit="11.4" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="14.8" upper_limit="18.0"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9.2" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.1" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="11.0" upper_limit="13.9"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6.5" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="7.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.2" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.8" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.8" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.4" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="14.0" upper_limit="17.2"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6.5" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="6.5" upper_limit="8.8"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.2" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.1" upper_limit="8.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.3" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.5" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Any(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="13.6" upper_limit="16.7"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.8" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Mild(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="7.0" upper_limit="9.3"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.4" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Moderate(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.2" upper_limit="7.3"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.5" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic medication(N=2076, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="10.9" upper_limit="13.8"/>
                    <measurement group_id="O2" value="7.6" lower_limit="5.8" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination</title>
        <time_frame>Within 7 days after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw. Here, 'N' signifies participants with known values reporting specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw. Here, 'N' signifies participants with known values reporting specific characteristic.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1823"/>
                <count group_id="O2" value="624"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C(N=1814, 621)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.4" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degreesC(N=1814, 621)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.9" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to&lt;39 degrees C(N=1814, 621)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to 40 degrees C (N=1814, 621)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C(N=1814, 621)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.4" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.7" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.2" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.5" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="6.3" upper_limit="8.8"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.0" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.7" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.8" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.6" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" lower_limit="30.4" upper_limit="34.7"/>
                    <measurement group_id="O2" value="21.6" lower_limit="18.5" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="15.9" upper_limit="19.4"/>
                    <measurement group_id="O2" value="12.5" lower_limit="10.0" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="11.8" upper_limit="15.0"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.3" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.1" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="37.1" upper_limit="41.6"/>
                    <measurement group_id="O2" value="24.5" lower_limit="21.2" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="17.2" upper_limit="20.8"/>
                    <measurement group_id="O2" value="13.1" lower_limit="10.6" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="17.0" upper_limit="20.6"/>
                    <measurement group_id="O2" value="9.6" lower_limit="7.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.1" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.9" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="11.1" upper_limit="14.2"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.6" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.5" upper_limit="9.0"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.9" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.3" upper_limit="5.2"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.4" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="15.2" upper_limit="18.7"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.6" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="7.7" upper_limit="10.3"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.7" upper_limit="8.1"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.7" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.7" upper_limit="1.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Any(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="11.1" upper_limit="14.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.7" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Mild(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.5" upper_limit="7.9"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.7" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Moderate(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.4" upper_limit="6.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.4" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.3" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic medication(N=1823, 624)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="11.3" upper_limit="14.5"/>
                    <measurement group_id="O2" value="6.6" lower_limit="4.8" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After First Vaccination</title>
        <time_frame>Within 30 days after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.62" lower_limit="7.5" upper_limit="9.8"/>
                    <measurement group_id="O2" value="7.30" lower_limit="5.6" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination</title>
        <time_frame>Within 30 days after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.10" lower_limit="8.9" upper_limit="11.4"/>
                    <measurement group_id="O2" value="10.10" lower_limit="8.0" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination</title>
        <time_frame>Within 30 days after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" lower_limit="8.0" upper_limit="10.7"/>
                    <measurement group_id="O2" value="7.24" lower_limit="5.4" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination</title>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.17" lower_limit="19.6" upper_limit="22.8"/>
                    <measurement group_id="O2" value="18.86" lower_limit="16.2" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase</title>
        <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.20" lower_limit="29.4" upper_limit="33.1"/>
                    <measurement group_id="O2" value="31.14" lower_limit="28.0" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination</title>
        <time_frame>Within 30 days after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination</title>
        <time_frame>Within 30 days after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination</title>
        <time_frame>Within 30 days after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination</title>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.3" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase</title>
        <time_frame>From 1 month after third vaccination up to 6 months after the third vaccination</time_frame>
        <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post-vaccination 3 blood draw to 6 months after last study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase</title>
          <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post-vaccination 3 blood draw to 6 months after last study vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.3" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.71" lower_limit="0.2" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase</title>
        <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.5" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.3" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period</title>
        <time_frame>From the first vaccination up to 6 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="0.9" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.7" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination</title>
        <time_frame>Within 30 days after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" lower_limit="3.2" upper_limit="4.7"/>
                    <measurement group_id="O2" value="3.77" lower_limit="2.6" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination</title>
        <time_frame>Within 30 days after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" lower_limit="3.8" upper_limit="5.6"/>
                    <measurement group_id="O2" value="4.91" lower_limit="3.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination</title>
        <time_frame>Within 30 days after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until until post third-vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until until post third-vaccination blood draw.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" lower_limit="4.1" upper_limit="6.1"/>
                    <measurement group_id="O2" value="3.85" lower_limit="2.5" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination</title>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" lower_limit="9.7" upper_limit="12.2"/>
                    <measurement group_id="O2" value="10.22" lower_limit="8.2" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase</title>
        <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.22" lower_limit="17.7" upper_limit="20.8"/>
                    <measurement group_id="O2" value="17.76" lower_limit="15.2" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase</title>
        <time_frame>From 1 month after third vaccination up to 6 months after the third vaccination</time_frame>
        <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post-vaccination 3 blood draw to 6 months after last study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase</title>
          <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post-vaccination 3 blood draw to 6 months after last study vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" lower_limit="5.9" upper_limit="8.2"/>
                    <measurement group_id="O2" value="6.68" lower_limit="4.9" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting at Least 1 Medically Attended Adverse Event Throughout the Study Period</title>
        <time_frame>From the first vaccination up to 6 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting at Least 1 Medically Attended Adverse Event Throughout the Study Period</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.89" lower_limit="20.3" upper_limit="23.6"/>
                    <measurement group_id="O2" value="21.17" lower_limit="18.4" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination</title>
        <time_frame>Within 30 days after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination</title>
        <time_frame>Within 30 days after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination</title>
        <time_frame>Within 30 days after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination</title>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase</title>
        <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.1" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase</title>
        <time_frame>From 1 month after third vaccination up to 6 months after the third vaccination</time_frame>
        <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post third-vaccination blood draw to 6 months after last study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase</title>
          <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post third-vaccination blood draw to 6 months after last study vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period</title>
        <time_frame>From the first vaccination up to 6 month after the third vaccination the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.2" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination</title>
        <time_frame>Within 30 minutes after first vaccination</time_frame>
        <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination</title>
          <population>Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2471"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination</title>
        <time_frame>Within 30 minutes after second vaccination</time_frame>
        <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination</title>
          <population>Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Third Vaccination</title>
        <time_frame>Within 30 minutes after third vaccination</time_frame>
        <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Third Vaccination</title>
          <population>Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Participants Missed School or Work Due to AE During the Vaccination Phase</title>
        <time_frame>From the first vaccination up to 1 month after the third vaccination</time_frame>
        <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available. Here, number of participants analyzed signifies subjects that were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Saline</title>
            <description>Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Participants Missed School or Work Due to AE During the Vaccination Phase</title>
          <population>Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available. Here, number of participants analyzed signifies subjects that were evaluable for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="10.75"/>
                    <measurement group_id="O2" value="5.6" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titers &gt;= Lower Limit of Quantification for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>Before first vaccination, 1 month after third vaccination</time_frame>
        <population>Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titers &gt;= Lower Limit of Quantification for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB3175[A29]:Before Vaccination 1 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="25.7" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3175[A29]:1 Month after Vaccination 3 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3010[A06]:Before Vaccination 1 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="11.9" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3010[A06]:1 Month after Vaccination 3 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="88.1" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3040[A07]:Before Vaccination 1 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="49.7" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3040[A07]:1 Month after Vaccination 3 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB824[A12]: Before Vaccination 1 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.8" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB824[A12]:1 Month after Vaccination 3 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="65.5" upper_limit="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1672[A15]:Before Vaccination 1 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="31.6" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1672[A15]:1 Month after Vaccination 3 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" lower_limit="87.9" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1989[A19]:Before Vaccination 1 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="23.5" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1989[A19]:1 Month after Vaccination 3 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.7" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1256[B03]:Before Vaccination 1 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="7.7" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1256[B03]:1 Month after Vaccination 3 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="81.8" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB866[B09]:Before Vaccination 1 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="18.6" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB866[B09]:1 Month after Vaccination 3 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="71.6" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB431[B15]:Before Vaccination 1 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="37.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB431[B15]:1 Month after Vaccination 3 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="93.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB648[B16]:Before Vaccination 1 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="17.1" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB648[B16]:1 Month after Vaccination 3 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="72.6" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, &gt;=1:128 for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>Before first vaccination, 1 month after third vaccination (Vac)</time_frame>
        <population>Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, &gt;=1:128 for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB3175[A29] 1:4 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="27.4" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3175[A29] 1:4 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3175[A29] 1:8 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="25.7" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3175[A29] 1:8 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3175[A29] 1:16 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="22.7" upper_limit="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3175[A29] 1:16 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.9" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3175[A29] 1:32 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="12.0" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3175[A29] 1:32 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="94.0" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3175[A29] 1:64 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="3.3" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3175[A29] 1:64 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="75.8" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3175[A29] 1:128 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.8" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3175[A29] 1:128 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" lower_limit="47.0" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3010[A06] 1:4 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="14.5" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3010[A06] 1:4 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="88.6" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3010[A06] 1:8 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="13.2" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3010[A06] 1:8 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="88.6" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3010[A06] 1:16 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="11.9" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3010[A06] 1:16 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="88.1" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3010[A06] 1:32 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.2" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3010 [A06] 1:32 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="81.5" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3010[A06] 1:64 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="3.9" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3010[A06] 1:64 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="64.8" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3010[A06] 1:128 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3010[A06] 1:128 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" lower_limit="35.9" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3040[A07] 1:4 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="49.7" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3040[A07] 1:4 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3040[A07] 1:8 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="49.7" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3040[A07] 1:8 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3040[A07] 1:16 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" lower_limit="49.4" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3040[A07] 1:16 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3040[A07] 1:32 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" lower_limit="36.8" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3040[A07] 1:32 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="88.6" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3040[A07] 1:64 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="16.5" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3040[A07] 1:64 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="67.3" upper_limit="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB3040[A07] 1:128 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB3040[A07] 1:128 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="24.0" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB824[A12] 1:4 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.1" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB824[A12] 1:4 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="68.2" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB824[A12] 1:8 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="5.3" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB824[A12] 1:8 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="67.8" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB824[A12] 1:16 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.8" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB824[A12] 1:16 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="65.5" upper_limit="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB824[A12] 1:32 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.8" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB824[A12] 1:32 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="40.5" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB824[A12] 1:64 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB824[A12] 1:64 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="11.6" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB824[A12] 1:128 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB824[A12] 1:128 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1672[A15] 1:4 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" lower_limit="33.7" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1672[A15] 1:4 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" lower_limit="87.9" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1672[A15] 1:8 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="31.6" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1672[A15] 1:8 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" lower_limit="87.9" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1672[A15] 1:16 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="27.8" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1672[A15] 1:16 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="87.5" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1672[A15] 1:32 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="15.9" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1672[A15] 1:32 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="77.5" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1672[A15] 1:64 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="4.4" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1672[A15] 1:64 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="48.4" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1672[A15] 1:128 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.6" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1672[A15] 1:128 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="14.6" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1989[A19] 1:4 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="33.4" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1989[A19] 1:4 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="93.2" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1989[A19] 1:8 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="31.4" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1989[A19] 1:8 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="93.2" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1989[A19] 1:16 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="23.5" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1989[A19] 1:16 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.7" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1989[A19] 1:32 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="14.0" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1989[A19] 1:32 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="88.5" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1989[A19] 1:64 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="5.9" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1989[A19] 1:64 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="72.2" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1989[A19] 1:128 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="5.9" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1989[A19] 1:128 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" lower_limit="43.7" upper_limit="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1256[B03] 1:4 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="9.3" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1256[B03] 1:4 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" lower_limit="82.2" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1256[B03] 1:8 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="7.7" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1256[B03] 1:8 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="81.8" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1256[B03] 1:16 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="6.8" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1256[B03] 1:16 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="80.6" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1256[B03] 1:32 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.8" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1256[B03] 1:32 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" lower_limit="73.0" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1256[B03] 1:64 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.5" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1256[B03] 1:64 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" lower_limit="50.3" upper_limit="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB1256[B03] 1:128 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB1256[B03] 1:128 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" lower_limit="25.3" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB866[B09] 1:4 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="19.6" upper_limit="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB866[B09] 1:4 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="73.1" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB866[B09] 1:8 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="18.6" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB866[B09] 1:8 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="71.6" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB866[B09] 1:16 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="14.3" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB866[B09] 1:16 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" lower_limit="67.7" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB866[B09] 1:32 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="8.3" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB866[B09] 1:32 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="46.5" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB866[B09] 1:64 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.5" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB866[B09] 1:64 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="22.5" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB866[B09] 1:128 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB866[B09] 1:128 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="9.1" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB431[B15] 1:4 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" lower_limit="38.9" upper_limit="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB431[B15] 1:4 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="94.4" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB431[B15] 1:8 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="37.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB431[B15] 1:8 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="93.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB431[B15] 1:16 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="35.4" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB431[B15] 1:16 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="93.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB431[B15] 1:32 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="18.8" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB431[B15] 1:32 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="79.6" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB431[B15] 1:64 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="5.1" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB431[B15] 1:64 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="50.4" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB431[B15] 1:128 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.4" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB431[B15] 1:128 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="17.7" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB648[B16] 1:4 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="19.4" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB648[B16] 1:4 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="73.8" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB648[B16] 1:8 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="17.1" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB648[B16] 1:8 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="72.6" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB648[B16] 1:16 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="14.4" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB648[B16] 1:16 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" lower_limit="71.1" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB648[B16] 1:32 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="8.2" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB648[B16] 1:32 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" lower_limit="55.1" upper_limit="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB648[B16] 1:64 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.6" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB648[B16] 1:64 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="28.8" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB648[B16] 1:128 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.6" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB648[B16] 1:128 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="12.6" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>Before first vaccination, 1 month after third vaccination</time_frame>
        <population>Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate assay results for the given antigen or strain. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate assay results for the given antigen or strain. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB3175[A29]:Before Vaccination 1 (N=280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.4" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3175[A29]:1 Month after Vaccination 3 (N=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="86.9" upper_limit="106.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3010[A06]:Before Vaccination 1 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="9.5" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3010[A06]:1 Month after Vaccination 3 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="61.8" upper_limit="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3040[A07]:Before Vaccination 1 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="12.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB3040[A07]:1 Month after Vaccination 3 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" lower_limit="54.6" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB824[A12]: Before Vaccination 1 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="8.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB824[A12]:1 Month after Vaccination 3 (N=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="18.8" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1672[A15]:Before Vaccination 1 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.1" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1672[A15]:1 Month after Vaccination 3 (N=279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="38.4" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1989[A19]:Before Vaccination 1 (N=278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="11.1" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1989[A19]:1 Month after Vaccination 3 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="77.7" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1256[B03]:Before Vaccination 1 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.7" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB1256[B03]:1 Month after Vaccination 3 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" lower_limit="42.2" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB866[B09]:Before Vaccination 1 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB866[B09]:1 Month after Vaccination 3 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="19.9" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB431[B15]:Before Vaccination 1 (N=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="8.1" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB431[B15]:1 Month after Vaccination 3 (N=276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="44.6" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB648[B16]:Before Vaccination 1 (N=270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.5" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB648[B16]:1 Month after Vaccination 3 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="22.8" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Composite hSBA Titer &gt;=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>Before vaccination 1, 1 Month after Vaccination 2</time_frame>
        <population>Evaluable immunogenicity population. Here, N signifies participants valid and determinate hSBA results on all 4 strains at the given time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Composite hSBA Titer &gt;=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, N signifies participants valid and determinate hSBA results on all 4 strains at the given time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before First Vaccination (N=1612)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="6.0" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 2 (N=1620)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" lower_limit="62.1" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>One month after second Bivalent rLP2086 vaccination</time_frame>
        <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at both the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at both the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80[A22] (N=1679)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" lower_limit="64.6" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001[A56] (N=1637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" lower_limit="84.1" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948[B24] (N=1658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="65.6" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707[B44] (N=1686)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" lower_limit="53.1" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>Before Vaccination (Vac) 1, 1 Month after Vac 2, 3</time_frame>
        <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vac 1: PMB80[A22] 1:16 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="31.3" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:16 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="82.9" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:16 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="92.2" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2001[A56] 1:8 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="29.9" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:8) (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="96.5" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:8 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.9" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2948[B24] 1:8 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="30.9" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:8 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="84.7" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3:PMB2948[B24] 1:8 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="93.9" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2707[B44] 1:8 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="9.6" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:8 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" lower_limit="66.1" upper_limit="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:8 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" lower_limit="85.8" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</title>
        <description>Results for PMB80[A22] 1:16, PMB2001[A56] 1:8, PMB2948[B24] 1:8 and PMB2707[B44] 1:8 are reported under secondary endpoint ‘Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1’.</description>
        <time_frame>Before Vaccination (Vac) 1, 1 Month after Vac 2, 3</time_frame>
        <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</title>
          <description>Results for PMB80[A22] 1:16, PMB2001[A56] 1:8, PMB2948[B24] 1:8 and PMB2707[B44] 1:8 are reported under secondary endpoint ‘Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1’.</description>
          <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vac 1: PMB80[A22] 1:4 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="39.7" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:4 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="84.5" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:4 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="93.1" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB80[A22] 1:8 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" lower_limit="36.5" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:8 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="83.9" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:8 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="92.9" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB80[A22] 1:32 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="17.8" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:32 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" lower_limit="69.0" upper_limit="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:32 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="83.8" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB80[A22] 1:64 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="8.3" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:64 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" lower_limit="47.4" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:64 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="62.1" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB80[A22] 1:128 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.6" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:128 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="27.8" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:128 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="39.4" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2001[A56] 1:4 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" lower_limit="33.6" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:4 (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="97.0" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:4 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.9" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2001[A56] 1:16 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="28.2" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:16 (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="96.1" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:16 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="98.7" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2001[A56] ] 1:32 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="22.3" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:32 (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="91.4" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:32 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="96.4" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2001[A56] 1:64 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="14.6" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2 :PMB2001[A56] 1:64 (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="78.9" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3 :PMB2001[A56] 1:64 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="89.0" upper_limit="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2001[A56] 1:128 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="5.9" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:128 (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" lower_limit="54.2" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:128 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="71.5" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2948[B24] 1:4 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="32.7" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:4 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="85.5" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:4 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="94.8" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2948[B24] 1:16 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="27.3" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:16 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" lower_limit="81.9" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:16 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="91.9" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2948[B24] 1:32 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="16.3" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:32 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" lower_limit="63.3" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:32 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" lower_limit="73.0" upper_limit="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2948[B24] 1:64 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="7.1" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:64 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" lower_limit="38.0" upper_limit="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:64 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="46.4" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2948[B24] 1:128 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.5" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:128 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="20.9" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:128 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="25.7" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2707[B44] 1:4 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="12.8" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:4 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="69.3" upper_limit="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:4 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="88.1" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2707[B44] 1:16 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="6.5" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:16 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" lower_limit="58.6" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:16 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="81.4" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2707[B44] 1:32 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:32 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" lower_limit="39.6" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:32 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" lower_limit="64.8" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2707[B44] 1:64 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.6" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:64 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" lower_limit="28.1" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:64 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" lower_limit="47.4" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vac 1: PMB2707[B44] 1:128 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.4" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:128 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="19.1" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:128 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="29.9" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>Before Vaccination (Vac) 1, 1 Month after Vac 2, 3</time_frame>
        <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80[A22]: Before Vac 1 (N=1704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="12.3" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB80[A22]: 1 Month after Vac 2 (N=1697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="46.2" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB80[A22]: 1 Month after Vac 3 (N=1714)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="70.2" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001[A56]: Before Vac 1 (N=1657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="8.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001[A56]: 1 Month after Vac 2 (N=1701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.3" lower_limit="107.9" upper_limit="121.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001[A56]: 1 Month after Vac 3 (N=1708)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.7" lower_limit="167.8" upper_limit="186.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948[B24]: Before Vac 1 (N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="7.3" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948[B24]: 1 Month after Vac 2 (N=1685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" lower_limit="33.7" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948[B24]: 1 Month after Vac 3 (N=1702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="46.8" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707[B44]: Before Vac 1 (N=1716)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.7" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707[B44]: 1 Month after Vac 2 (N=1693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="20.9" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707[B44]: 1 Month after Vac 3 (N=1703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="44.2" upper_limit="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination</title>
        <time_frame>One month after third bivalent rLP2086 vaccination</time_frame>
        <population>Data was not reported because 3-fold rise analyses was not performed as per change in planned analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination</title>
          <population>Data was not reported because 3-fold rise analyses was not performed as per change in planned analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</title>
        <time_frame>One month after third bivalent rLP2086 vaccination</time_frame>
        <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 rLP2086</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1</title>
          <population>Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80[A22]: 1 Month after Vac 3 (N=1695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="87.4" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001[A56]: 1 Month after Vac 3 (N=1642)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="94.2" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948[B24]: 1 Month after Vac 3 (N=1675)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="85.4" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707[B44]: 1 Month after Vac 3(N=1696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="79.9" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs: recorded from first vaccination through 6 months after third vaccination. Participants recorded pre-specified reactogenicity events (local reactions, systemic events) in electronic diary within 7 days after first, second and third vaccination</time_frame>
      <desc>All AEs collected on case report form are shown below as having been collected via non-systematic assessment. All events reported via electronic diary (reactogenicity events) are shown below as having been collected via systematic assessment. Reactogenicity events are grouped by all severities and doses combined.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 rLP2086</title>
          <description>Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Saline</title>
          <description>Saline on a 0-, 2-, 6- month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Otosalpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2193" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="567" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38.0 degrees C -Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="2432"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="807"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting - Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea-Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="497" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache - Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1440" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="391" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue -Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1576" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="411" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Chills - Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="697" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain -Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="916" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain -Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="723" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="808"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="822"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="2471"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="822"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Local Reactions">Pain at injection site - Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2184" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness -Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="537" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="808"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling -Any (reactogenicity event)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="612" subjects_at_risk="2438"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="808"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

